Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PMVP 
Pmv Pharmaceuticals Inc (PMVP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/25/2025: PMVP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.24% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.45M USD | Price to earnings Ratio - | 1Y Target Price 5.8 |
Price to earnings Ratio - | 1Y Target Price 5.8 | ||
Volume (30-day avg) 139353 | Beta 1.45 | 52 Weeks Range 0.96 - 2.26 | Updated Date 04/1/2025 |
52 Weeks Range 0.96 - 2.26 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.92% | Return on Equity (TTM) -29.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -111656372 | Price to Sales(TTM) - |
Enterprise Value -111656372 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.24 | Shares Outstanding 51933600 | Shares Floating 34570123 |
Shares Outstanding 51933600 | Shares Floating 34570123 | ||
Percent Insiders 2.49 | Percent Institutions 81.32 |
Analyst Ratings
Rating 4.83 | Target Price 5.8 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pmv Pharmaceuticals Inc
Company Overview
History and Background
PMV Pharmaceuticals, Inc. is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. Founded in 2013, it focuses on restoring p53 activity in cancers with wild-type p53 genes.
Core Business Areas
- Research and Development: Focuses on discovering and developing small molecule therapeutics that selectively target and restore the function of wild-type p53.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its lead drug candidates in various cancer types.
- Partnerships and Licensing: Collaborates with other pharmaceutical and biotechnology companies to advance the development and commercialization of its products.
Leadership and Structure
The company is led by a management team with experience in drug discovery, clinical development, and commercialization. Its organizational structure includes research, clinical, regulatory, and commercial functions.
Top Products and Market Share
Key Offerings
- PCM-075: PCM-075 is PMV Pharmaceuticals' lead product candidate, an oral small molecule that is designed to selectively bind to and activate wild-type p53 protein. It is currently in Phase 1/2 clinical trials. There is no current market share data available as the product is still in development. Competitors include companies developing other p53-targeted therapies.
Market Dynamics
Industry Overview
The oncology drug market is large and growing, driven by an aging population and increasing cancer incidence. The market is competitive, with many companies developing novel therapies.
Positioning
PMV Pharmaceuticals is positioned as a precision oncology company focused on developing tumor-agnostic therapies. Its competitive advantage lies in its expertise in p53 biology and its small molecule drug discovery platform.
Total Addressable Market (TAM)
The TAM for p53-targeted therapies is significant, given the high prevalence of cancers with wild-type p53. PMV is positioned to capture a portion of this market with successful development and commercialization of PCM-075.
Upturn SWOT Analysis
Strengths
- Novel approach targeting wild-type p53
- Proprietary small molecule drug discovery platform
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- High risk of clinical trial failure
- Reliance on a single lead product candidate
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Expanding clinical development to additional cancer types
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies or assets
- Securing regulatory approvals and commercializing PCM-075
Threats
- Competition from other oncology drug developers
- Regulatory hurdles and delays
- Unfavorable clinical trial results
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- ARRY
- SNY
Competitive Landscape
PMV Pharmaceuticals faces competition from other companies developing oncology drugs, including those targeting p53. Its competitive advantage lies in its novel approach and small molecule drug discovery platform. However, competitors are bigger and have established revenue streams.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to R&D advancements and clinical trial progress.
Future Projections: Future growth depends on the successful development and commercialization of PCM-075. Analyst estimates depend on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing PCM-075 through clinical trials and expanding its pipeline of p53-targeted therapies.
Summary
PMV Pharmaceuticals is a clinical-stage biotech company focused on developing p53-targeted therapies, particularly PCM-075. Its novel approach presents a significant opportunity in the oncology space, but also carries considerable risks associated with drug development. Success hinges on favorable clinical trial results and securing regulatory approvals. Financial stability and competition from larger pharma companies are critical considerations.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
MDGL
Madrigal Pharmaceuticals Inc
MDGL
Madrigal Pharmaceuticals Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share information is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pmv Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2020-09-25 | Co-Founder, CEO, President & Director Dr. David H. Mack Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 47 | Website https://www.pmvpharma.com |
Full time employees 47 | Website https://www.pmvpharma.com | ||
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.